CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2017-01-01
|
| Serija: | Kidney International Reports |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S2468024916300717 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|